Investor Relations

Enabling Gene-silencing at the DNA Level

At Oncogenuity, we’re developing novel treatments for genetically driven cancers and coronaviruses. Our novel platform uses oligonucleotides to suppress specific gene mutations at the DNA level without impacting wild-type DNA sequences and potentially limiting off-target toxicity.

Unlocking the Potential of ONCOlogues

Oncogenuity, Inc. is a biopharmaceutical company focused on the development and commercialization of ONCOlogues for the treatment of genetically driven cancers and coronaviruses. Oncogenuity’s lead product candidate targets a KRAS mutation, G12D. Oncogenuity is located in New York City and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).